Novel kinase-activating genetic events in non-small cell lung carcinomas

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality.
• Identifying novel druggable targets is crucial for improving NSCLC treatment outcomes.
• Previous research has identified several actionable mutations, but a subset of NSCLC patients lack these known alterations.

Purpose of the Study:

• To identify novel, potentially druggable kinase-activating alterations in a cohort of NSCLC patients.
• To investigate genetic alterations in NSCLCs from young-onset and/or female non-smokers, who often present with distinct molecular profiles.
• To assess the frequency of specific gene fusions and kinase domain mutations in NSCLC.

Main Methods:

• RNA next-generation sequencing (NGS) was performed on 650 protein kinase genes in 89 NSCLC samples.
• Samples were selected from patients negative for common activating mutations (e.g., EGFR, ALK, ROS1).
• Identified translocations were further analyzed in larger NSCLC cohorts, and kinase domain mutations were assessed using CADD scores.

Main Results:

• RNA sequencing identified 32 in-frame rearrangements, including 17 translocations affecting tyrosine kinase domains.
• Two additional tumors with ADK::KAT6B rearrangement and one with RPS6KB1::VMP1 fusion were found in a larger cohort.
• No recurrent kinase domain mutations (CADD > 25) were identified in over 551 additional NSCLCs, and CLIP1::LTK fusions were not re-observed.

Conclusions:

• The study highlights a scarcity of previously unidentified kinase-activating alterations in NSCLC.
• The identified gene fusions (ADK::KAT6B, RPS6KB1::VMP1) represent rare events.
• Further research may be needed to explore other non-kinase-driven therapeutic strategies for NSCLC.